TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Community Based Management of Fast Breathing in Infants Aged < 60 Days in Low-income Settlements of Karachi

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria~* Young infant (0-59 days of age)~* Fast breathing i.e., respiratory rate ≥60 breaths/min~* O2 Saturation ≥90%~* Resident of catchment area (to ensure complaint and follow up)~* Refused hospitalization and investigations~* Informed consent is provided by a parent (or legal guardian).~Exclusion Criteria:~* Preterm infants (born \<37 weeks)~* Presence of audible murmur~* Any concurrent signs of severe infection:~* not feeding well~* movement only when stimulated~* severe chest in-drawing~* axillary temperature ≥38.0oC or ≤35.5oC~* Any sign of being critically ill (Cyanosis, bulging fontanel, unable to feed, unable to cry, apnoea, convulsions, unconscious, persistent vomiting)~* Weight \<1800gm at the time of presentation~* Major congenital malformations or suspected chromosomal abnormalities~* Hospitalization for illness in the last two weeks~* Previous inclusion in the study

- Gender: ALL
- Minimum Age: None
- Maximum Age: 59 Days
- Healthy Volunteers: f

Study Arms:
- Amoxicillin (Type: ACTIVE_COMPARATOR): This is an active intervention
- Sugar Syrup (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: The Oslo Study of Clonidine in Elderly Patients With Delirium

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient \> 65 years old admitted to the Medical department~* Delirium or subsyndromal delirium diagnosed within the last 48 hours~* Signed informed consent from patient or relatives~* Expected cooperation of the patients for the treatment and follow up~Exclusion Criteria:~* Symptomatic bradycardia, bradycardia due to sick-sinus-syndrome, second- or third- degree AV-block (not treated With pacemaker) or any other reason causing HR \<50 bpm at time of inclusion~* Symptomatic hypotension or orthostatic hypotension, or a systolic BP \<120 at the time of inclusion~* Ischemic stroke within the last 3 months or critical peripheral ischemia~* Acute coronary syndrome, unstable or severe coronary heart disease (symptoms at minimal physical activity; NYHA 3 and 4) and moderate to severe heart failure (NYHA 3 and 4).~* A diagnosis of polyneuropathy or pheochromocytoma~* Renal insufficiency (estimated GFR\<30 ml/min according to the MDRD formula).~* Body weight \< 45 kg.~* Considered as moribund on admission.~* Not able to take oral medications~* Current use of tricyclic antidepressants, monoamine reuptake inhibitors or ciclosporin~* Previously included in this study~* Adverse reactions to clonidine or excipients (lactose, saccharose)~* Not speaking or reading Norwegian~* Any other condition as evaluated by the treating physician~* Admitted to the ICU

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Clonidine (Type: EXPERIMENTAL): Clonidine administered orally:~Day 1/loading doses: 75µg every 3rd hour until maximum 4 doses. Day 2-7/maintenance doses: 75µg BID. Duration of treatment is maximum 7 days.
- Placebo (sugar pill) (Type: PLACEBO_COMPARATOR): Placebo administered orally (identical capsula as for expirimental drug):~Day 1/loading doases: 75µg every 3rd hour until maximum 4 doses. Day 2-7/maintenance doses: 75µg BID. Duration of treatment is maximum 7 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Gastrografin for Treating Small Bowel Obstruction in Children

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosed small bowel obstruction by a surgeon or physician~* Patient has undergo 24 hours of monitoring and non-surgical management (NG tube decompression, IV fluids, and NPO)~* Patients are between 6 month and 18 years of age at time of diagnosis~Exclusion Criteria:~* Abnormal levels of thyroid stimulating hormone (TSH) or thyroxine (T4)~* Prior thyroid surgery~* Receiving thyroid hormone replacement therapy~* Allergy to medical or non-medial ingredients in Gastrografin~* Weight of less than 10kg at time of diagnosis

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Gastrografin Arm (Type: EXPERIMENTAL): Patients will receive a single dose of undiluted Gastrografin via the nasogastric tube at 24 hours after admission for small bowel obstruction. The dose of Gastrografin will be proportional to the patient's weight and age and will be based off of the recommendations from the drug manufacturer. Dosages will range from 30 ml for infants to children less than 5 years old and 60 ml for children 5-18 years and will not be diluted.
- Control Arm (Type: EXPERIMENTAL): Patients will receive a single dose of saline solution via the nasogastric tube at 24 hours after admission for small bowel obstruction. The volume of saline solution will be proportional to the volume of Gastrografin patients of similar weight and age would receive.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study of CCNU (Lomustine) Plus Dasatinib in Recurrent Glioblastoma (GBM)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with histological or cytological proven glioblastoma multiforme~* Recurrent or progressive disease documented by magnetic resonance imaging (MRI)~* World Health Organization (WHO) Performance status 0 - 2~* Patient may have been operated for recurrence~* For non operated patients, recurrent disease must be at least one bidimensionally measurable target lesion with one diameter of at least 2cm~* Patients must be on a stable or decreasing dose of corticosteroids for at least 1 week prior to baseline MRI~Exclusion Criteria:~* Patients with histological or cytological proven glioblastoma multiforme~* Completion of radiotherapy to the brain less than 3 months prior to registration/randomization~* Prior treatment with high dose radiotherapy, stereotactic radiosurgery or internal radiation therapy~* Previous or current malignancy at other sites within prior 3 years

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dasatinib (Type: ACTIVE_COMPARATOR): None
- Lomustine (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: TraStuzumAb-Radiotherapy : Impact on the Cerebral Prevention

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with breast cancer, expressing HER2-NEU (score +++ in ICH or ++ and amplification on FISH or CISH, SISH)~* Visceral metastasis, only or multiple~* First line metastasis treatment by Trastuzumab in association with chemotherapy~* Good general conditions: OMS=\<2 or Karnofsky \>=70%~* Age \> 18 years and \< 70 years~* Life expectancy \>=3 mois~* No Trastuzumab since more of 6 months~* No cerebral metastasis (MRI)~* Efficacy contraception for women with genital capacities~* Consent signed by the patient~Exclusion Criteria~* Contraindication to IRM~* Psychiatric decease~* Prior cerebral radiotherapy,~* Geographical constraint, compromising the fallow of patients~* Infectious or other serious pathology, likely to stop the treatment~* Positive serology (HIV, hBC, hBS)~* Inclusion in an other clinical trial or in the 4 weeks before th inclusion~* Pregnant or breastfeeding women

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Arm A (Type: ACTIVE_COMPARATOR): Without cerebral prophylactic radiation
- Arm B (Type: EXPERIMENTAL): With cerebral prophylactic radiation

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Thalidomide Versus Infliximab in New Onset Crohn's Disease With Poor Prognostic Factors

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age at diagnosis \<18 years and \>=6 years~* New diagnosis of CD based on Porto criteria~* CD with inflammatory phenotype (non-penetrating, non-fistulizing) and with no need for surgery except for perinal fistulas~* Presence of at least one of the following risk factors for poor prognosis:~  * fistulizing perianal disease~ * pan-enteric disease~ * disease extension \> 60 cm~ * severe growth delay (height z-score \< -2 DS)~ * severe osteoporosis (z score \< -2 DS)~ * hypoalbuminemia (\< 3g/dL) or high C-reactive protein (2 times higher the normal range)~* Acceptance of the Risk Evaluation and Mitigation Strategy (REMS) program for reducing the teratogenic risk.~Exclusion Criteria:~* ongoing pregnancy~* presence of peripheral neuropathy~* HIV~* patients with transplanted organs~* ongoing major infections or other severe diseases~* participation to other experimental studies.

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Thalidomide (Type: EXPERIMENTAL): Thalidomide is a immunomodulatory and antiangiogenetic drug with anti tumor necrosis factor (TNF) alpha properties
- Infliximab (Type: ACTIVE_COMPARATOR): Infliximab is a chimeric monoclonal antibody against TNF alpha

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Prospective Clinical Research Project Evaluating The Effects of Soft Contact Lenses on Higher Order Visual Aberrations

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~All patients of any race and sex between the ages of 18-35 years of age who are not currently wearing contact lenses at their initial presentation. Only patients who voluntarily agree to participate in the study will be included. These potential subjects would be selected after reviewing and signing the Informed Consent (IC) as well as HIPAA authorization forms. The Principal Investigator (PI) or his designee will introduce the study to the patient, thoroughly explaining the details of the study. Copies of the forms will be placed in the patient medical record as well as given to study patient.~Exclusion Criteria:~Patients under the age of 18 or over the age of 35 will be excluded. Patients with any ocular pathology, previous eye surgery and/or uveitis will be excluded. Also, any patient who does not choose to participate will be excluded.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 35 Years
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Erythropoietin and Pediatric Cardiac Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 6 weeks to 18 years~* Requiring open heart surgery for congenital heart defect -Parents able to speak English and document informed consent -~Exclusion Criteria:~* Received erythropoietin within past 30 days~* Previous adverse reaction to erythropoietin or to albumin~* History of neurological disorder -Laboratory evidence of kidney or liver dysfunction -

- Gender: ALL
- Minimum Age: 6 Weeks
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- 3 (Type: PLACEBO_COMPARATOR): acyanotic placebo
- 4 (Type: EXPERIMENTAL): acyanotic erythropoietin

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: GLS-1200 Topical Nasal Spray to Prevent SARS-CoV-2 Infection (COVID-19)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18 or older~* Able to provide informed consent~* Able and willing to comply with study procedures~* Able and willing to utilize an approved form of pregnancy prevention for women of child bearing potential through to the end of treatment~Exclusion Criteria:~* Know allergy to quinine, quinidine, or mefloquine~* Confirmed prior positive test for SARS-CoV-2~* Treatment within the past 2 weeks with chloroquine, hydroxychloroquine, or remdesivir~* Pregnancy or documentation of pregnancy by pre-treatment urine test or breast feeding or plans to become pregnant during the course of the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- GLS-1200 (Type: EXPERIMENTAL): 1 mL of GLS-1200 per nostril, TID
- 0.9 %Saline (Type: PLACEBO_COMPARATOR): 1 mL of 0.9% Saline per nostril, TID

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Open-Label Extension Study of Ubenimex in Patients With Pulmonary Arterial Hypertension (WHO Group 1)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients must have completed Study EIG-UBX-001 through Week 24.~* In the opinion of the Principal Investigator, has been generally compliant with study requirements during Study EIG-UBX-001.~* Agrees to use a medically acceptable method of contraception throughout the entire study period.~* Willing and able to comply with scheduled visits, treatment plans, and laboratory tests and other study procedures.~Exclusion Criteria:~* Is pregnant or lactating.~* Concurrent regular use of another leukotriene pathway inhibitor.~* Any reason that, in the opinion of the investigator, precludes the patient from participating in the study.~  1. Any condition that is unstable or that could jeopardize the safety of the patient and his/her compliance in the study~ 2. A serious uncontrolled medical disorder/condition that in the opinion of the investigator would impair the ability of the patient to receive protocol therapy~* An ongoing, drug-related, serious adverse event (SAE).~* Significant/chronic renal insufficiency.~* Transaminases (alanine transaminase, aspartate transaminase) levels \>3 × upper limit of normal (ULN) and/or bilirubin level \>2 × ULN.~* Absolute neutrophil count \<1500 mm3.~* Hemoglobin concentration \<9 g/dL at Screening.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- ubenimex (Type: EXPERIMENTAL): ubenimex capsules 150 mg three times a day (TID), administered orally, minimum of 24 weeks for all patients.~The maximum anticipated time an individual patient will participate will vary because treatment will continue until the last patient enrolled has received at least 24 weeks of open-label treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Sildenafil in Heart Failure With Reactive Pulmonary Hypertension

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Known chronic heart failure appropriately treated with Angiotensin converting enzyme (ACE) inhibitors and beta blockers, unless contraindicated or poorly tolerated~* indication for right heart catheterization~* pulmonary artery mean pressure \>25 mmHg~* pulmonary capillary wedge pressure \> 15 mmHg~* pulmonary vascular resistance \> 3 Wood units~Exclusion Criteria:~* hypersensitivity, allergy, or intolerable side effect to sildenafil~* history of primary pulmonary hypertension, connective tissue disorder, severe chronic obstructive pulmonary disorder (COPD), pulmonary embolism, or left to right shunt~* co-morbidities, limited exercise intolerance:~  * morbid obesity (BMI \>40)~ * COPD with oxygen dependence~ * severe peripheral vascular disease with intermittent claudication~ * status post amputation of lower extremity at any level~ * severe degenerative joint disease preventing normal walking

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo three times per day, orally
- Sildenafil (Type: ACTIVE_COMPARATOR): Sildenafil 20 mg three times per day, orally

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The Virtual Asthma Clinic

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Physician diagnosis of asthma at the time of enrolment.~2. The forced expiratory volume in one second (FEV1) at base line will be at least 50 percent of the predicted value.~3. Evidence of at least 12% increase in FEV1 following inhaled bronchodilator or airway hyperreactivity as defined by a standard methacholine challenge study.~Exclusion Criteria:~1. Concurrent disease likely to require regular physician contact (e.g. congestive heart failure).~2. A separate diagnosis or other pulmonary disease (e.g. pulmonary fibrosis or chronic bronchitis).~3. An inability to access the Internet on a regular basis.~4. Inability or unwillingness to give informed consent or to complete online health related quality of life questionnaires.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: PLACEBO_COMPARATOR): Patient does not have 24/7 access to a Certified Asthma Educator.
- 2 (Type: ACTIVE_COMPARATOR): Patient has 24/7 access to a Certified Asthma Educator.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Transcranial Magnetic Stimulation Treatment for Generalized Anxiety Disorder

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Participated in the study DIEF003523.1, received sham placebo TMS and achieved \< 50% improvement in HARS at 3 month follow-up.~* Fluency in English~* Capacity to understand the nature of the study and willingness to sign informed consent form~Exclusion Criteria:~* History of epilepsy or head trauma (LOC \> 5 minutes) within the past 6 months~* Lifetime history of increased intracranial pressure, seizure disorder, stroke, brain tumor, multiple sclerosis, or brain surgery~* A review of patient medications by the study physician indicates an increased risk of seizure~* An active autoimmune, endocrine, viral, or vascular disorder affecting the brain; any unstable cardiac disease; hypertension; or severe renal or liver insufficiency~* Substance use disorder or PTSD within the past 6 months~* Lifetime bipolar disorder, obsessive-compulsive disorder (OCD), psychotic disorder, mental retardation, or pervasive developmental disorder~* Any psychotic features, including dementia or delirium~* Concurrent psychotherapy and unwillingness to discontinue~* Medication change within the past 4 weeks~* Current serious suicidal or homicidal ideation, and/or serious suicidal attempt within the past 6 months~* Serious, unstable, or terminal medical condition or clinically judged too psychiatrically unstable to participate in the study~* Any contraindication for participation in MRI scan

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- rTMS Treatment (Type: EXPERIMENTAL): Clinical participants will receive rTMS

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues